TapImmune Inc. (OTCMKTS:TPIV) Recovers Some Ground

TapImmune Inc. (OTCMKTS:TPIV) added 10.18% to its market value yesterday – but will it keep its gains?

There’s no simple answer to that question. As is usually the case with OTC Markets pharmaceutical companies, it all lies in the hands of the noteholders. Why?

Because, as it is currently, Portfolio Services Ltd. beneficially owns 48.3% of the company’s common stock. That’s 20 million shares, and another 20 million issuable on demand. Suffice it to say that if even a fraction of those shares found their way on the market, the ticker could plummet right down to the bottom of the charts.

Investors on the company’s message boards are currently arguing that such a move would be contrary to the interests of the noteholder itself, and truth be told, that argument has some merit. However, much stranger things have happened on the OTC Markets in the past, so it wouldn’t be a surprise to see that come to pass as well.

That possibility aside, the company’s current situation looks pretty good. Although TPIV‘s latest report certainly left a lot to be desired, the Mayo Clinic deal and the $13.3 million grant from the US Department of Defense Breast Cancer Research Program are causes for optimism that have given investors high hopes for the company in the long term.

However, said investors should never forget that although TPIV may have made a couple of good announcements recently, it is still an OTC Markets pharmaceutical pennystock, with all of the risks that represents. This is why said investors would do well to be diligent and vigilant when dealing with TPIV stock.